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Patients in intensive care unit are prescribed large numbers of drugs, highlighting the need to study 
potential Drug-Drug Interactions in this environment. The aim of this study was to delineate the 
prevalence and risk of potential drug-drug interactions between medications administered to patients 
in an ICU. This cross-sectional observational study was conducted during 12 months, in an adult ICU 
of a teaching hospital. Inclusion criteria were: prescriptions with 2 or more drugs of patients admitted 
to the ICU for > 24 hours and age of ≥18 years. Potential Drug-Drug Interactions were quantified and 
classified through MicromedexTM database. The 369 prescriptions included in this study had 205 different 
drugs, with an average of 13.04 ± 4.26 (mean ± standard deviation) drugs per prescription. Potential 
Drug-Drug Interactions were identified in 89% of these, with an average of 5.00 ± 5.06 interactions per 
prescription. Of the 405 different pairs of potentially interacting drugs identified, moderate and major 
interactions were present in 74% and 67% of prescriptions, respectively. The most prevalent interaction 
was between dipyrone and enoxaparin (35.8%), though its clinical occurrence was not observed in this 
study. The number of potential Drug-Drug Interactions showed significant positive correlations with 
the length of stay in the intensive care unit, and with the number of prescribed drugs. Acknowledging 
the high potential for Drug-Drug Interactions in the ICU represents an important step toward improving 
patient safety and best therapy results.
Uniterms: Potential drug-drug interactions. Intensive care unit. Patient safety. University hospitals.
INTRODUCTION
A Drug-Drug Interaction is a pharmacological or 
clinical response to the administration of two or more 
drugs, which is different from the response triggered by the 
individual use of these agents (Tatro, 2012). Knowledge 
of the main characteristics of these interactions and access 
to databases with detailed information on them, including 
the mechanisms involved and their potential severity, 
can prevent the resulting adverse events and/or assist in 
their clinical management (Papadopoulos, Smithburger, 
2010; Magro, Moretti, Leone, 2012; Dubova et al., 2007). 
When the interactions present in the prescription are 
theoretically evaluated through databases and not by their 
actual occurrence, they are considered potential (Brunton 
et al., 2011).
In clinical practice, potential Drug-Drug Interactions 
(pDDIs) can lead to serious problems, such as severe 
adverse events and ineffective drug therapy (Mannheimer, 
Eliasson, 2010; Reimche, Forster, Van Walraven, 2011). 
Patients in the intensive care unit (ICU) routinely receive 
large numbers of drugs with pDDIs, highlighting the 
need to study these interactions in this environment 
(Papadopoulos, Smithburger, 2010; Reimche, Forster, 
Van Walraven, 2011; Kopp et al., 2006). Reducing 
unnecessary risks to the patient is improving patient safety. 
As the risks profiles are established, reduction of risks and 
avoidable adverse events can also improve patient safety. 
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(Benkirane et al., 2009; Cullen et al., 1997; Kopp et al., 
2006; Mcdowell, Ferner, Ferner, 2009).
PDDIs often are between drugs that are metabolized 
by the same cytochrome P450 (CYP450) enzymes, 
and/or due to the administration of drugs that inhibit 
or induce these enzymes systems (Spriet et al., 2009; 
Klein, Gueorguieva, Aarons, 2012; Mouly, Meune, 
Bergmann, 2009). Drugs metabolized by this route include 
midazolam, tacrolimus, cyclosporine, and phenytoin, all 
of which are widely used in the ICU. CYP450 inducers 
and inhibitors include drugs such as amiodarone, 
fluconazole, and carbamazepine, which are often used in 
the ICU (Papadopoulos, Smithburger, 2010; Mannheimer, 
Eliasson, 2010).
The large number of pDDIs between drugs prescribed 
to ICU patients has been documented by several studies 
(Smithburger, Kane-Gill, Seybert, 2012; Smithburger et 
al., 2010; Rivkin, Yin, 2011; Kane-Gill et al., 2012). A 
recent study conducted in the USA showed that 46.3% 
of ICU prescriptions included pDDIs (Smithburger, 
Kane-Gill, Seybert, 2012), while Brazilian studies have 
reported a prevalence of 67% or 70% (Hammes et al., 
2008; Moreira, Cassiani, 2011). In addition, there are 
international differences in drug availability that may 
contribute to regional variations in the number of pDDIs 
(Moreira, Cassiani, 2011; Moura, Prado, Acurcio, 2011; 
Moura et al., 2012).
Preventing adverse events caused by pDDIs and 
managing these interactions are central to the Clinical 
Pharmacy practice in an ICU (Rudis, Brandl, 2000). This 
justifies the elevated number of publications in this matter 
(Rivkin, Yin, 2011; Kane, Weber, Dasta, 2003; Moura et 
al., 2012; Papadopoulos, Smithburger, 2010; Mannheimer, 
Eliasson, 2010.; Moreira, Cassiani, 2011). 
The aim of this study was to evaluate the prevalence 
of pDDIs in prescriptions in the ICU of a university 
hospital in the Brazilian public health system. Were 
quantified and classified the pDDIs per their degree of 
severity, to analyse the risks to patient management. Both 
pharmacokinetic and pharmacodynamic interactions were 
evaluated, as all PDDIs were included. 
METHODS
This cross-sectional observational study was 
conducted for 12 months (from August 2014 to September 
2015) in the adult ICU of Clinics Hospital of the State 
University of Campinas (HC-UNICAMP) that has 403 
beds. Inclusion criteria were: prescriptions with 2 or more 
drugs of patients admitted to the ICU for > 24 hours and 
age of ≥ 18 years, one random prescription per patient. 
Patients that were admitted and discharged to the ICU on 
weekends did not have their prescriptions included in the 
study. Data was retrieved from patients’ prescriptions and 
the hospital’s database. This research received approval 
from the Ethics Committee of the School of Medical 
Sciences, University of Campinas (Campinas, São Paulo, 
Brazil); protocol number CAAE: 0882.0.146.000-10. 
The search for pDDIs within the prescriptions 
was performed using the MicromedexTM database 
(MICROMEDEX, 2011), where pDDIs are classified as 
follows: contraindicated (the drugs are contraindicated 
for concurrent use); major (the interaction may be 
life-threatening and/or require medical intervention to 
minimize or prevent serious adverse effects); moderate 
(the interaction may result in exacerbation of the patient’s 
condition and/or require an alternative therapy); or minor 
(the interaction would have limited clinical effects; 
manifestations may include an increase in the frequency or 
severity of the side effects but generally would not require 
a major change in therapy) In addition, it was possible to 
correlate the presence of pDDIs with other parameters 
including length of stay, death in the ICU, the number of 
prescribed drugs, patient age, and gender. This analysis 
was conducted by critically analysing pDDI data with a 
database of ICU patient clinical records that was updated 
daily. The purpose of this database is to continuously 
monitor the safety and quality of the ICU and it provides 
a very useful research tool. The database was organized by 
admission number, assuring patient confidentiality. Only 
professionals and researchers directly involved had access 
to the records database. 
All the analysed medication information was 
transposed to a Microsoft ExcelTM spreadsheet and 
interaction information was constantly updated during the 
study, through frequent consultations of the MicromedexTM 
database (MICROMEDEX, 2011). 
After analysis, these drugs were classified 
according to the Anatomical Therapeutic Chemical 
(ATC) classification system that is recommended by the 
WHO for drug utilization studies (WHO Collaborating 
Centre for Drug Statistics Methodology, 2012). This study 
determined the frequency of usage of prescribed drugs that 
were monitored by the FAST HUG strategy. FAST HUG is 
a mnemonic used to facilitate the continuous monitoring 
of patients in relation to: Feeding; Analgesia; Sedation; 
Thromboembolic prophylaxis; Head-of-bed elevation; 
stress Ulcer prophylaxis; and Glycaemic control. These 
parameters should be monitored daily and relate to factors 
involving drug therapy, as well as non-pharmacological 
actions (Vincent, 2005).
To determine a statistically significant sample size, a 
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pilot study with 88 prescriptions was conducted for three 
months. Descriptive statistics were used to describe the 
sample profile. To analyse correlations between variables, 
the Spearman correlation coefficient (rs) was used. The 
significance level for statistical tests was 5%, or p < 0.05. 
The Statistical Analysis System (SAS) for Windows, 
version 9.2 (SAS Institute Inc., 2002-2008, Cary, NC, 
USA), was used for statistical analyses.
RESULTS
During the study period, the prescriptions of 
369 patients were analysed over one 24-h period, one 
prescription per patient. The study group (205 men and 
164 women) represented approximately 37% of the 
population admitted into the ICU during this period. The 
study group was heterogeneous, comprising both surgical 
and clinical patients. Since this study was performed at a 
general ICU, the reasons for patient hospitalization were 
very diverse, including elective surgeries that demanded 
postoperative intensive care, grave clinical conditions 
that required life support, such as stroke, among others. 
During the assessed period, 205 different drugs were 
prescribed. Table I describes the clinical characteristics 
and demographics of the patients. 
Many of the most commonly prescribed drugs were 
associated with standard protocols in ICU medicine, as 
illustrated in Table II. This Table shows the percentage 
of patients prescribed each of the indicated drugs and 
highlights their relation to FAST HUG protocols. Table II 
also shows the frequency of pDDIs present in prescriptions 
involving these drugs.
During the study, 1844 pDDIs were identified, 
quantified, and classified; these included 405 different 
pDDIs between the prescribed drugs.
At least one pDDI was identified in 89% of the 
patient prescriptions included in this study, and those 
classified as moderate and major were present in 74% and 
67% of the prescriptions, respectively. A wide variety of 
pDDIs types were identified. A total of 405 interactions 
were found: 12 contraindicated; 130 major; 225 moderate; 
and 38 minor. For 52 of these interactions, the management 
recommendations state that their concomitant use should 
be avoided and suggest the suspension of one drug, 
while monitoring is recommended for 306 of the pDDIs. 
Dipyrone was involved in the largest number of pDDIs. 
This analgesic and antipyretic drug is widely used in 
Brazil but has a restricted use in several countries and is 
not available in the USA. Table III provides information 
on the 10 most common pDDIs and their frequencies 
in the analysed prescriptions. The 12 contraindicated 
pDDIs observed have extremely careful management 
recommendations to either suspend use of one of the 
medications or when keeping both drugs, cautiously watch 
for adverse event signs. 
The results were subjected to statistical analysis to 
evaluate the correlations between the number of pDDIs 
and the number of prescribed drugs, the length of stay 
in ICU (days), and patient age. There was a statistically 
significant correlation showing that the higher the total 
of pDDIs in a prescription, the longer the ICU stay (p = 
0.0027), and major pDDIs were related to longer ICU stay 
(p < 0001). Also, there were more pDDIs in prescriptions 
with more drugs (p < 0001). The other variables analysed 
did not show statistically significant correlations. 
DISCUSSION
With 89% of the analysed prescriptions including 
at least one pDDI, the need for their evaluation and 
monitoring is evident. Other studies, with different 
designs and sample sizes, have confirmed this alarmingly 
high number, which included all classes of pDDIs (from 
contraindicated to minor) (Papadopoulos, Smithburger, 
2010; Reimche, Forster, Van Walraven, 2011; Kane-Gill 
et al., 2012; Arques-Armoiry et al., 2010; Rodrigues et al., 
2015). The relationship between the number of prescribed 
drugs and the number of pDDIs has been reported 
TABLE I - Patient clinical and demographic characteristics
Characteristics Values
Number of patients 369
Age in years [median ± standard 
deviation]
57.0 ± 14.6
Gender [male n (%)] 205 (55.5) 
Number of drugs per prescription 
[median ± standard deviation]
13.0 ± 4.3
Length of stay in the ICU in days 
[median ± standard deviation]
13.3 ± 16.5
Clinical Specialties [n (%)] 
Neurology 
Cardiology 
Gastroenterology 
Vascular surgery 
Others
 
117 (31.7) 
98 (26.5) 
73 (19.8) 
39 (10.6) 
42 (10.8)
Reasons for ICU admission [n (%)] 
Post-surgery 
Septic shock 
Sepsis 
Others
 
254 (68.8) 
18(4.8) 
10 (2.7) 
87 (23.6)
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TABLE II - Prescribed drugs related to FAST HUG and their potential Drug-Drug Interactions (pDDIs)
FAST HUG Drug ATC class
Prescription 
frequency 
[n(%)]
pDDI frequency 
in prescription 
[n(%)]
(A) Analgesia
Dipyrone Analgesic N02A 342(92.7) 239(64.8)
Morphine Analgesic N02B 172(46.6) 68(18.4)
Fentanyl 52(14.1) 80(21.7)
Tramadol 51(13.8) 7(1.9)
Acetaminophen Analgesic N02A 29(7.8) 5(1.3)
Acetaminophen/Codeine Analgesic N02B 9(2.4) 2(0.5)
Meperidine 3(0.8) 14(3.8)
Nalbuphine 2(0.5) 1(0.3)
(S) Sedation
Midazolam Psycholeptic N05C 62(16.8) 95(25.7)
Diazepam Psycholeptic N05B 29(7.8) 24(6.5)
Haloperidol
Antipsychotic N05A
17(4.6) 26(7.0)
Chlorpromazine 7(1.9) 32(8.7)
(T) Thromboembolic prophylaxis
Enoxaparin 
Heparin
Antithrombotic 
agent B01A
151(40.9) 
35(9.5)
166(45.0) 
7(1.9)
(U) Stress Ulcer prophylaxis
Omeprazole 
Ranitidine
Peptic Ulcer 
Treatment A02B
148(40.1) 
160(43.4)
80(21.7) 
6(1.6)
(G) Glycemic Control Insulin Regular Human Insulin, Isophane Antidiabetic A10A
334(90.5) 
14(3.8)
59(16.0) 
9(2.4)
TABLE III - Most frequent relevant potential Drug-Drug Interactions 
Drug interaction
Prescription 
Frequency 
[n (%)]
Severity Potential risk Recommendation
Enoxaparin + Dipyrone 132 (35.8) Major Bleeding Suspension or monitoring
Insulin + Acetylsalicylic acid 64 (17.3) Moderate Hypoglycemia Monitoring
Enalapril + Acetylsalicylic acid 43 (11.6) Moderate Decreased 
antihypertensive efficacy
Monitoring
Amlodipine + Simvastatin 34 (9.2) Major Myopathy and rhabdomyolysis Monitoring
Miconazole + Warfarin 30 (8.1) Major Bleeding Monitoring
Darunavir + Warfarin 29 (7.8) Moderate Alterations of Warfarin levels Monitoring
Dipyrone + Metoprolol 28 (7.6) Moderate Decreased 
antihypertensive efficacy
Monitoring
Omeprazole + Midazolam 26 (7.0) Moderate Increased 
benzodiazepines toxicity
Monitoring
Amiodarone + Simvastatin 24 (6.5) Major Myopathy and rhabdomyolysis
Suspension or 
monitoring
Insulin + Octreotide 24 (6.5) Moderate Hypoglycemia Monitoring
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previously. This correlation illustrates the inherent risk 
of prescribing a wide range of drugs (Papadopoulos, 
Smithburger, 2010; Reimche, Forster, Van Walraven, 
2011; Kane-Gill et al., 2012).
Moderate pDDIs comprise much of interactions 
found in this study and are also the most frequently 
reported by other ICU researches (Smithburger, Kane-
Gill, Seybert, 2012; Smithburger et al., 2010; Hammes 
et al., 2008; Rodrigues et al., 2015). In this study, the 
interactions classified as contraindicated, major, and 
moderate by MicromedexTM were clinically relevant. 
In addition, the real impact of these pDDIs should be 
determined on an individual basis and this requires 
careful evaluation of the risk-benefit relationship between 
the suspension of therapy, or its maintenance with 
continuous monitoring. This approach is followed by most 
management guidelines, which always perform a risk-
benefit analysis (MICROMEDEX, 2011). Moreover, it is 
worth remembering that drugs such as dipyrone are often 
prescribed “if needed” and are not usually administered 
concomitantly with the potentially interacting drugs.
Clinical relevancy of pDDIs in intensive therapy is 
not a subject with settled theoretical concepts. Although 
clinical decision support systems, as Micromedex™, 
contribute to this discussion, the inherent risk of each 
pDDI in clinical practice is individually evaluated using 
the theoretical information along with the specifics of each 
case. It is not possible to observe complete agreement 
among classification of severity of pDDI in intensive 
therapy publishing (Papadopoulos, Smithburger, 2010; 
Smithburger et al., 2010; Rodrigues et al., 2015).
The prescriptions analysed in this study demonstrated 
the major therapeutic drug classes are associated with 
standardized protocols employed in the ICU, highlighting 
the correlation between the frequency of these prescribed 
drugs and international guidelines that promote continuous 
checking of seven clinical parameters that are essential 
to the safety of critically ill patients, known by the 
mnemonic, FAST HUG (Vincent, 2005). 
The ICU in the present study used international 
guidelines and FAST HUG, making its therapeutic profile 
very similar and comparable ICUs in the USA and Europe. 
However, there are some differences in the specific drugs 
used in ICUs in Brazil and other countries owing to 
international differences in drug licensing. An example 
of this difference is the use of dipyrone, which is widely 
prescribed in Brazil but is not marketed in the USA or in 
some European countries. The higher number of pDDIs 
in Brazil and in developing countries may reflect the more 
recent development of clinical pharmacy services with a 
focus on adverse events and their prevention, as compared 
to countries with well-established services (Dubova et 
al., 2007; Hammes et al., 2008; Moreira, Cassiani, 2011).
The significant correlation between the number 
of pDDIs and the length of stay in the ICU observed in 
this study was consistent with earlier studies (Moreira, 
Cassiani, 2011). Although this correlation exists, it is not 
obvious whether the pDDIs caused the increased stay, 
or vice-versa. It is possible that the number of pDDIs is 
elevated in patients with prolonged ICU stay because these 
patients tend to be seriously ill and therefore require a 
larger number of drugs. Again, greater exposure to adverse 
events caused by pDDIs may have increased the length of 
stay. This issue should be investigated in future studies. 
Analgesics (dipyrone), antithrombotic (enoxaparin, 
warfarin), antifungal (miconazole), antidiabetics (insulin), 
beta blockers (metoprolol), ECA inhibitors (enalapril) 
drugs are involved in the 10 most occurring pDDI on this 
study, as were identified by other studies (Askari et al., 
2013; Uijtendaal et al., 2014). The pDDI pair dipyrone 
and enoxaparin was the most prevalent in this study and 
is usually little noticed by the intensivists. However, it 
cannot be ignored since it is classified as a major pDDI 
and has good documentation (MICROMEDEX, 2011). 
Other pDDIs with acknowledged adverse events, such as 
antidiabetic agents, have an important clinical relevancy 
in an intensive care environment (Vanham et al., 2016). 
Identifying which pDDIs are clinically relevant and 
manage their alerts to the multidisciplinary team is 
essential to improve patient safety (Rodrigues et al., 2015).
The present study delineated the most common 
pDDIs in this ICU. This study had limitations, since it 
was not possible to randomize the data collection and a 
convenience sampling approach was used. In addition, the 
results of this research were based on the MicromedexTM 
version available during the study period. 
The prescription of potentially dangerous drugs 
is more frequent in the ICU, where there is also a 
higher number of adverse events than in other hospital 
departments and reinforces the need for vigilance with 
respect to pDDIs (Manias et al., 2014; Aljadhey et al., 
2013).
CONCLUSION
This study showed that the clear majority of ICU 
prescriptions had at least one pDDI and the most prevalent 
ones were classified as moderate. The theoretical risks 
of these pDDIs are known, but their real impact should 
be determined on an individual basis evaluating the 
risk-benefit relationship between the suspension of 
therapy, or its maintenance with continuous monitoring. 
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Acknowledging the high potential for Drug-Drug 
Interactions in the ICU represents an important step toward 
improving patient safety and best therapy results.
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